Fireside Chat: Moving Beyond Slowing Fibrosis to Define the Biology, Data & Trial Designs Needed to Stop or Reverse Disease to Deliver Meaningful Patient Benefit

• Reflecting on the discoveries that have enabled antifibrotic therapies to slow disease progression, and debating whether these same insights are sufficient to guide therapies that stop or reverse fibrosis
• Defining what true fibrosis regression means, including ECM remodeling, fibrinolysis, fibroblast deactivation, restored tissue architecture and functional recovery
• Determining whether different cell types, molecular mechanisms, datasets, biomarkers, and clinical trial designs are needed to distinguish therapies that slow progression from those that actively reverse fibrotic disease

Speakers:

Thomas fabre

Senior Principal Scientist

Pfizer

David lagares

Chief Executive Officer, President & Founder

Zenon Biotech